I feel much the same as you, but the choice won't be ours. Some investors may oppose it, but if management supports it, I believe it will pass easily. If it were a hostile takeover that required a vote, that might be a different matter.
I like the idea of an equity partner, that would provide the funding and experience to get through adding multiple new trials as well as assisting with the distribution and sales of DCVax-L. Note, I didn't say manufacturer because this is not a bulk manufacturing process, which BP is used to, each vaccine is unique and we will either rely on our contractors, or we'll be using the Flaskwork technology that we already own. In many ways I believe that Flaskwork turns into a major profit center for the company.
Gary
Market Data 
Markets 
